Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial

DNA vectors have been widely used as a priming of poxvirus vaccine in prime/boost regimens. Whether the number of DNA impacts qualitatively or quantitatively the immune response is not fully explored. With the aim to reinforce T-cell responses by optimizing the prime-boost regimen, the multicentric...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:PLoS Pathog
Egile Nagusiak: Lévy, Yves, Lacabaratz, Christine, Ellefsen-Lavoie, Kim, Stöhr, Wolfgang, Lelièvre, Jean-Daniel, Bart, Pierre-Alexandre, Launay, Odile, Weber, Jonathan, Salzberger, Bernd, Wiedemann, Aurélie, Surenaud, Mathieu, Koelle, David M., Wolf, Hans, Wagner, Ralf, Rieux, Véronique, Montefiori, David C., Yates, Nicole L., Tomaras, Georgia D., Gottardo, Raphael, Mayer, Bryan, Ding, Song, Thiébaut, Rodolphe, McCormack, Sheena, Chêne, Geneviève, Pantaleo, Giuseppe
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Public Library of Science 2020
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7319597/
https://ncbi.nlm.nih.gov/pubmed/32589686
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.ppat.1008522
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak